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Abstract
Maresin conjugates in tissue regeneration (MCTR) are a new family of evolutionarily con-
served chemical signals that orchestrate host responses to promote tissue regeneration
and resolution of infections. Herein, we identified the novel MCTR3 and established rank
order potencies and matched the stereochemistries of MCTR1, MCTR2 and MCTR3 using
material prepared by total organic synthesis and mediators isolated from both mouse and
human systems. MCTR3 was produced from endogenous substrate by E. coli activated
human macrophages and identified in sepsis patients. Each of the three synthetic MCTR
dose-dependently (1–100nM) accelerated tissue regeneration in planaria by 0.6–0.9 days.
When administered at the onset or peak of inflammation, each of the MCTR promoted reso-
lution of E. coli infections in mice. They increased bacterial phagocytosis by exudate leuko-
cytes (~15–50%), limited neutrophil infiltration (~20–50%), promoted efferocytosis (~30%)
and reduced eicosanoids. MCTR1 and MCTR2 upregulated human neutrophil and macro-
phage phagocytic responses where MCTR3 also proved to possess potent actions. These
results establish the complete stereochemistry and rank order potencies for MCTR1,
MCTR2 and MCTR3 that provide novel resolution moduli in regulating host responses to
clear infections and promote tissue regeneration.
Introduction
We recently identified, in self-resolving exudates, novel mediators that resolve infections [1–3] as
well as regulate tissue regeneration [2]. These novel chemical signals link the resolution of infec-
tious inflammatory exudates to the process of tissue regeneration. The acute inflammatory
response, when self-contained, plays a critical role in limiting bacterial invasion to promote
wound repair and tissue regeneration (for recent reviews, see [3, 4]). This protective response is
orchestrated by autacoids at the site of inflammation [3, 5, 6]. Arachidonic acid-derived eicosa-
noids, namely prostaglandins and leukotrienes, are produced during the initiation stage of the
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inflammatory response leading to vascular leak and leukocyte recruitment [5, 6]. During resolu-
tion of acute inflammation, a process termed lipid mediator class switching occurs that leads to
the formation of novel potent pro-resolving mediators [3]. This new genus of specialized pro-
resolving mediators (SPM) include the n-3 essential fatty acid derived resolvins, protectins and
maresins that possess leukocyte directed actions promoting the resolution of acute inflammation
[1, 3, 7]. These mediators also stimulate the clearance of apoptotic cells and debris, playing funda-
mental role(s) in inflammation-resolution [3, 4, 8]. Resolution mediators such as Annexin A1 and
Lipoxin A4 are critical in human control of tissue repair [9], and maresins in regeneration [2].
The biological actions of these pro-resolving mediators are stereochemically selective
reflecting their routes of biosynthesis [3]. Therefore, establishing the complete stereochemical
assignment and rank order potencies of lipid mediators are of considerable interest. Indeed
establishing the complete stereochemistry of resolvins [3] enabled the confirmation and exten-
sion of the potent and diverse biological actions of these new mediators, for example, identifi-
cation of Resolvin D1’s actions in treating postoperative cognitive decline [10] and protective
actions of Maresin 1 (MaR1) in murine colitis [11].
Maresins (macrophage mediators in resolving inflammation) by definition are formed via
14-lipoxygenation of docosahexaenoic acid and promote resolution of acute inflammation and
tissue regeneration [2, 3, 12]. Recently, we uncovered a new series of bioactive peptide-lipid
conjugated mediators that are produced during the later stages of self-resolving infections [2]
that are also present in human sepsis patients [13]. These were termed maresin conjugates in
tissue regeneration (MCTR) because they regulate mechanisms in inflammation-resolution as
well as tissue regeneration establishing links between local inflammatory exudates and tissue
regeneration via novel chemical signals [2, 3]. The structure for MCTR1 is 13-glutathionyl,
14-hydroxy-docosahexaenoic acid, and that of MCTR2, 13-cysteinylglycinyl, 14-hydroxy-
docosahexaenoic acid. In this report, we identified MCTR3 as 13-cysteinyl, 14-hydroxy-doco-
sahexaenoic acid and established the potencies of MCTRs in the clearance of infections and tis-
sue regeneration as well as their complete stereochemistry.
Materials and Methods
Lipid mediator metabololipidomics
All samples for LC-MS-MS-based lipidomics were subject to solid-phase extraction [13]. Prior
to sample extraction, d4-LTB4, d4-PGE2 and d5-LTC4, representing each region in the chro-
matographic analysis (500 pg each), were added to permit quantification. Extracted samples
were analyzed by a liquid chromatography-tandem mass spectrometry system, QTrap 5500 for
eicosanoids (ABSciex) or QTrap 6500 (ABSciex) for MCTR equipped with an Agilent HP1100
binary pump and diode-array detector. An Agilent Eclipse Plus C18 column (100 mm × 4.6
mm × 1.8 μm) was used with a gradient of methanol/water/acetic acid of 80:20:0.01 (v/v/v) to
100:0:0.01 at 0.5 ml/min flow rate for eicosanoids and 55:45:0.1 (v/v/v) to 100:0:0.1 for MCTR.
MCTR1, MCTR2 and MCTR3 were each prepared by total organic synthesis; purity of each
was>98% and their structures confirmed using NMR [14].
To monitor and quantify the levels of targeted LMs, we used multiple reaction monitoring
(MRM) with signature ion fragments for each molecule (six diagnostic ions and calibration
curves). The following transitions were employed for MCTRs: MCTR1 m/z 650>191, MCTR2
521>191 and MCTR3 464>191 [13].
Planaria tissue regeneration
Planaria (Dugesia japonica) were kept in water (Poland Spring; Nestle Waters North America,
Stamford, CT, USA) at 18°C. All animals were starved for at least 7 days before the experiments.
MCTR Rank Order Potencies in Infection-Resolution
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hydroxy-docosahexaenoic acid; Ri, resolution
interval; SPM, specialized pro-resolving mediators;
T50, time to 50% regeneration; TR, retention time;
TRImax, maximum tissue regeneration.
Tissue regeneration was assessed as described [2]. In brief, planaria were subjected to head
resection postocularly (surgical injury). The posterior portions of the planaria were then placed
in spring water containing 0.01% EtOH, or MCTR at indicated concentrations. The extent of tis-
sue regeneration during a 6-day period was determined using captured images of regenerating
blastemas at regular intervals (24 h). These images were analyzed using ImageJ software (NIH,
Bethesda, MD, USA) to give a tissue regeneration index (TRI) [2].
E. coli peritonitis
Peritonitis experiments were conducted as in [2]. Briefly, FVB mice (6-8-weeks old), purchased
from Charles River Laboratories (Wilmington, MA, USA) were fed ad libitum Laboratory
RodentDiet 20–5058 (LabDiet; Purina Mills, St. Louis, MO, USA) and housed at a maximum
of four animals per cage and maintained in 12:12 hour light-dark cycles. Mouse experimental
procedures were approved by the Standing Committee on Animals of Harvard Medical School
(Protocol 02570) and complied with institutional and U.S. National Institutes of Health (NIH)
guidelines. No surgical procedures were conducted and no analgesics were administered. Mice
were euthanized by overdose of isoflurane via inhalation in saturated atmosphere, followed by
cervical dislocation. If recovery from procedure is compromised as assessed by increase in self
grooming, aggressive behavior or rapid movements, self-mutilation, absent activity, lack of eat-
ing or drinking, abdominal distention or redness and heat over abdominal area, humane end-
point in Protocol 02570 requires that mice must be euthanized immediately by isoflurane
overdose, followed by cervical dislocation. During this procedure, animals did not experience
more than slight or momentary pain or distress and no animals died prior to experimental end-
point. E. coli (serotypeO6:K2:H1) was cultured in Luria-Bertani broth and harvested at midlog
phase (OD600 nm, ~0.5 absorbance units). In determined experiments mice were administered
MCTR1, MCTR2, MCTR3 (50ng/mouse) or vehicle via intraperitoneal (i.p) injection and after
5 minutes inoculated with E. coli (105 CFU/mouse). Exudates were collected at the indicated
intervals and leukocyte populations as well as bacterial phagocytosis and macrophage efferocy-
tosis determined using flow cytometry and fluorescent-labeled antibodies [2]. In select experi-
ments, mice were inoculated with E. coli (105 CFU/mouse), after 12h administered MCTR1,
MCTR2, MCTR3 (100ng/mouse) or vehicle i.p. and exudates collected after 24h with leukocyte
populations and bacterial phagocytosis determined as above.
Phagocytosis
Human macrophages and neutrophils were prepared from peripheral blood leukocytes [2] and
in accordance with the approved Partners Human Research Committee Protocol
(1999P001297). Briefly, macrophages were plated in 96-well plates (5x104 cells per well) for
24h, neutrophils were plated in 96-well plates (1x105 cells per well) for 30 min and phagocyto-
sis or efferocytosis was assessed as in [2]. For efferocytosis, apoptotic PMNs were obtained by
culturing neutrophils overnight in PBS-/- (5x106 cells/ml). Apoptotic human PMNs were
labeled with bisBenzimide trihydrochloride (Sigma-Aldrich). For efferocytosis, human macro-
phages were incubated with MCTR1, MCTR2, MCTR3 (1pM-10nM), or vehicle then labeled
apoptotic PMNs (2.5x105 cells) and incubated for 60 min (37°C pH 7.45). Fluorescence was
measured using a SpectraMax M3 plate reader (Molecular Devices, Sunnyvale, CA, USA), and
results were analyzed using SoftMax Pro (Molecular Devices). In select experiments, macro-
phages were incubated for 15 minutes with vehicle, MCTR1, MCTR2, MCTR3 (1pM-10nM)
or a mixture of MCTR1+MCTR2, MCTR2+MCTR3, or MCTR1+MCTR3 (0.1nM each). Bac-
Light Green Bacterial Stain (Life Technologies, Eugene, OR, USA) labeled E. coli (2.5x 106
CFU/well) were added, cells incubated for 60 min (37°C pH 7.45) and fluorescence assessed
MCTR Rank Order Potencies in Infection-Resolution
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using the fluorescence plate reader. In separate experiments, human neutrophils were incu-
bated with MCTR1, MCTR2, MCTR3 (1pM-10nM), or vehicle then with BacLight Green Bac-
terial Stain-labeled E. coli (2.5x 106 CFU/well; 60 min; 37°C pH 7.45) and fluorescence assessed
as above.
Additionally, PMN survival was assessed. PMN were plated in 12-well plates at 5x106 cells/
mL in PBS with calcium and magnesium. At time zero, either PBS alone or 10nMMCTR1,
MCTR2, or MCTR3 was added to PMN. Cells were incubated at 37°C with 5% CO2 for 24 or
48 hours, collected and analyzed by flow cytometry. Cells were surface-stained against Annexin
V and Propidium Iodide (Molecular Probes, FITC AnnexinV/Dead Cell Apoptosis, Eugene,
OR). Cell staining was evaluated using FACSCanto II flow cytometer (BD Biosciences, San
Jose, CA) and results were analyzed using FlowJo software (Tree Star, Ashland, OR).
For real-time imaging, macrophages were plated onto 8-well chamber slides (0.1 x106 cells/
well in PBS+/+). The Nunc™ Lab-Tek™ II chamber system (Thermo Scientific, cat. # 15434) con-
sists of a removable polystyrene media chamber attached to a glass microscope slide. The
chamber slides were kept in a Stage Top Incubation system for microscopes equipped with a
built-in digital gas mixer and temperature regulator (TOKAI HIT model INUF-K14). MCTR1,
MCTR2 MCTR3 (1nM) or vehicle (PBS containing 0.01% EtOH) was added to macrophages
for 15 min, followed by BacLight Green-labeled E. coli (2.5 x 106 CFU). Images were then
acquired every 6 min for 2h (37°C) with a Keyence BZ-9000 (BIOREVO) inverted fluorescence
phase-contrast microscope (20X objective) equipped with a monochrome/color switching
camera using BZ-II Viewer software (Keyence, Itasca, IL, USA). Green fluorescence intensity
was quantified using BZ-II Analyzer.
Statistical analysis
All results are expressed as the mean ± SEM. Differences between groups were compared using
Student’s T-test (for two groups), 1-way ANOVA (multiple groups) followed by post hoc Bon-
ferroni test, or 2-way ANOVA (multiple groups, multiple time points) followed by post hoc
Bonferroni or Tukey tests as appropriate. The criterion for statistical significance was p< 0.05.
Results
We recently determined the complete stereochemistry of a key intermediate in maresin biosyn-
thetic pathway 13S,14S-epoxy maresin [12], the proposed intermediate and immediate precur-
sor in MCTR production (Fig 1A and [2]). Given that MCTR are produced in several
biological systems, we obtained MCTR isolated from human macrophages, murine infectious
exudates, and sepsis patients (Fig 1B–1D) to assess if they coeluted in LC-MS-MS and give
MS-MS spectra identical to compounds independently prepared by total organic synthesis (Fig
1E). To determine the rank order potencies and stereochemistry for each MCTR, it was essen-
tial to use stereochemically pure precursors [14] because the endogenous mediators MCTR are
produced in pico- to nanogram quantities that are not suitable for NMR analysis to obtain ste-
reochemical assignments. In liquid chromatography tandem mass spectrometry, MCTR1 gave
a distinct sharp peak with retention time (TR) = 9.8 min, MCTR2 gave a sharp peak with TR =
9.1 min and the new MCTR3 gave a sharp peak with TR = 10.3 min.
Co-injection of the synthetic with authentic MCTR1 demonstrated co-elution at TR = 9.8
min (n = 3 macrophage preparations). Similarly, co-injection of synthetic MCTR2 and
MCTR3 with MCTR isolated from human macrophages demonstrate co-elution with the
respective authentic products (n = 3 macrophage preparations). Assessment of the MS-MS
spectra for the material obtained by total organic synthesis gave essentially identical fragmenta-
tion spectra to those obtained with authentic material (Fig 1F and cf. [2, 13]). These mass
MCTR Rank Order Potencies in Infection-Resolution
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spectra gave fragmentations and ions that were consistent with the deduced structures, where
MCTR1 gave a parent ion with m/z of 650, MCTR2 an m/z of 521 and MCTR3 that of m/z
464. MCTR3 gave diagnostic ions at m/z 191, 205, 235 and 343 (see Fig 1F inset) as well as 464
(M+H), 325 (343-H2O), 227 (245-H2O), 213 (231-H2O), The ultraviolet chromophores for
each of the three molecules were characteristic of conjugated triene double bond systems with
an allylic auxochrome where the λmax
MeOH for MCTR1, MCTR2 and MCTR3 was 281nm.
Thus, the stereochemically defined MCTR1, 2 and 3 each matched the endogenous molecules,
permitting the identification of MCTR3.
Fig 1. Endogenous MCTR from humanmacrophages, sepsis plasma andmouse infectious exudatesmatch synthetic materials. (A) MCTR
biosynthetic pathway. (B-D) Endogenous MCTR were obtained from (B) human macrophages (1x107 cells/ml) incubated with E. coli (5x108 CFU/ml; 30min,
37°C, PBS+/+; n = 3 macrophage preparations). (C) Sepsis plasma (n = 3 patients) (D) mice were inoculated with 105 CFU/mouse E. coli and exudates
collected after 24h (n = 3 mice). Products were extracted using C18 SPE and profiled using lipid mediator metabololipidomics. (E) Synthetic material. Results
representative of 3 separate determinations. (F) MS-MS spectra for synthetic MCTR1, MCTR2 and MCTR3. Results are representative of d = 3.
doi:10.1371/journal.pone.0149319.g001
MCTR Rank Order Potencies in Infection-Resolution
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Having matched the physical properties of synthetic, stereochemically defined materials
with those of endogenously produced MCTRs from both human and murine systems, we next
required assessment of their potent biological actions. Given that MCTRs display tissue regen-
erative actions, we assessed the ability of each synthetic MCTR to promote tissue regeneration.
Planaria were surgically injured by rapidly removing the head portion of the animals and tissue
regeneration was followed over time [2]. Planaria undergo both physiological and restorative
regeneration via evolutionarily conserved pathways, making this an ideal system to character-
ize novel chemical signals involved in tissue regeneration [15]. When planaria were kept with
vehicle alone, maximum tissue regeneration (TRI max) occurred within ~6 days with time to
50% regeneration (T50) occurring by ~2.7 days. Incubation of planaria with MCTR1 led to
acceleration in tissue regeneration with a reduction in T50 from ~2.7 days to ~2 days when pla-
naria were incubated with 100nM of MCTR1 and to ~1.9 days when incubated with 1nM (Fig
2A). MCTR2 also accelerated tissue regeneration with planaria, where incubation of surgically
injured planaria with MCTR2 reduced T50 to ~1.8 days (Fig 2B) and at 1nM reduced T50 to
~1.9 days. The new MCTR3 also demonstrated potent tissue regenerative actions that were
dose dependent (Fig 2C). Assessment of their relative potencies at stimulating tissue regenera-
tion demonstrated that MCTR3 and MCTR2 were the most potent of the three, followed by
MCTR1. Hence, MCTR3MCTR2>MCTR1 (Fig 2D).
Given the increased incidence of bacterial infections [1, 16] and that MCTR1 and MCTR2
each displays potent actions promoting resolution of infections, we could now test whether
each of the stereochemically pure MCTR1, 2 and 3 also carried these actions in murine infec-
tions. E. coli (1x105 CFU/mouse) inoculation gave a self-resolving inflammatory response with
maximal neutrophil infiltration at ~12 h that subsequently declined, which gave a calculated
resolution interval (Ri) of ~12h (Fig 3A). MCTR1 (50ng/mouse) injection immediately prior to
E. coli inoculation gave a significant reduction in neutrophil infiltration at the 12 h interval,
and shortened the resolution interval from ~12h to ~4h (Fig 3A). Administration of MCTR2
also gave significant reductions in exudate leukocyte counts (~50%), a shortening in the Ri to
~2h and an increase in phagocytosis of E. coli (~50%) by exudate leukocytes. These results with
synthetic MCTRs are in accordance with published findings with biologically produced
MCTRs [2] and confirm the potent actions of these novel mediators in infections. Of note,
MCTR3 given immediately prior to E. coli inoculation reduced exudate neutrophil levels by
~54%, shortening the Ri from 12 h to 3 h (Fig 3C). In addition to reducing neutrophil infiltra-
tion, each of three MCTR significantly increased leukocyte phagocytosis of E. coli, with
MCTR2 and MCTR3 displaying the highest potencies (Fig 3D). MCTR1 was the most potent
in stimulating macrophage efferocytosis (Fig 3E), a key defining pro-resolving action.
We also tested whether MCTR carry pro-resolving actions when administered at the peak
of inflammation during E. coli infections. Administration of MCTR1 at the peak of inflamma-
tion (12h interval) gave reductions in exudate neutrophil counts at 24h and shortened Ri to
~10 h (Fig 3F). In mice given MCTR2 we found reductions in exudate neutrophil counts
(~50%) giving an Ri of ~7 h (Fig 3G). At equal doses, MCTR3 also promoted the resolution of
E. coli infections, reducing exudate neutrophil counts by ~50% and shortening the Ri to ~9 h
(Fig 3G and 3H). Together these results demonstrate the potent biological actions of MCTR1
and MCTR2, confirming their original structural assignments (Fig 3I and 3J). Moreover, we
describe here the unexpected actions of MCTR3 in accelerating the resolution of E. coli infec-
tions and establish the rank order potencies in promoting the resolution of infectious-
inflammation.
During acute inflammation, classic eicosanoids can propagate the response by promoting
vascular leakage (PGD2 and PGE2) and leukocyte recruitment (LTB4) and in some instances
are associated with the switch to chronic inflammation [5, 6]. Given the potent bioactions of
MCTR Rank Order Potencies in Infection-Resolution
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MCTR during infections, we assessed whether they regulated local eicosanoids during infec-
tions. MCTR1 at 100ng/mouse displayed the highest potency at counter-regulating exudate
eicosanoids (n = 3 mice per group; p<0.05), significantly reduced PGD2 (~55%), PGE2
(~60%), PGF2α (~50%), TxB2 (~50%) and LTB4 (~50%). MCTR2 gave a select regulation of
eicosanoids including PGD2 (~70%) and PGF2α (~35%) that were statistically reduced in the
infectious exudates at the 12h interval, whereas MCTR3 significantly reduced PGD2 (~50%),
PGE2 (~50%), PGF2α (~50%) and TxB2 (~50%), thus suggesting that each of these novel mole-
cules activates distinct counter-regulatory mechanisms in controlling exudate eicosanoids dur-
ing infections (MCTR1>>MCTR3>MCTR2).
Toward human translation, we validated the bioactions of these novel molecules with
human primary leukocytes. Incubation of MCTR1 (1pM-10nM) with human macrophages
gave dose-dependent increases (15–50%) in macrophage phagocytosis of E. coli with a maxi-
mum at ~1pM (Fig 4A). In addition, MCTR1 stimulated the efferocytosis of apoptotic neutro-
phils by macrophages (10–20% increase above vehicle; n = 8 macrophage preparations
p<0.05), a key macrophage response in resolution cellular mechanisms [3, 4]. MCTR1, at a
Fig 2. Synthetic MCTR dose dependently accelerate tissue regeneration in planaria. (A-C) Planaria
were surgically injured, then kept in water containing (A) MCTR1 (1 or 100nM) (B) MCTR2 (1 or 100nM) (C)
MCTR3 (1 or 100nM) or vehicle (water containing 0.01% EtOH), and tissue regeneration was assessed (see
Materials and Methods for details). TRI50, time to 50% regeneration. (D) Rank order potency at promoting
tissue regeneration measured at Day 2 post-surgery for 100nMMCTR. Results are mean ± SEM. n = 8
planaria per group. *p<0.05, **p<0.01, #p<0.001, ##p<0.0001 vs. surgical Injury + vehicle; §p<0.05 vs.
surgical Injury + MCTR1.
doi:10.1371/journal.pone.0149319.g002
MCTR Rank Order Potencies in Infection-Resolution
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Fig 3. MCTRs accelerate resolution of E. coli infections. (A-E) Mice were administered (A) MCTR1, (B) MCTR2, (C) MCTR3 (50ng) or vehicle (saline
containing 0.1% EtOH) via i.p injection; after 5 min they were inoculated with E. coli (105 CFU/mouse) and exudates collected at the indicated time intervals;
peritoneal leukocyte counts and resolution indices were determined (See Materials and Methods). (D) E. coli phagocytosis by exudate leukocytes was
determined as median fluorescence units (MFI) in the CD11b+E. coli+ population at 12h (E) Exudate macrophage efferocytosis was determined as MFI in the
F4/80+Ly6G+ population. (F-J) Mice were inoculated with E. coli (105 CFU/mouse). After 12h, exudates were collected or (F) MCTR1, (G) MCTR2, (H)
MCTR Rank Order Potencies in Infection-Resolution
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similar concentration range, also dose-dependently promoted phagocytosis of bacteria by
human neutrophils with maxima at 100pM (30–70% increase above vehicle; p<0.05). Similar
results were obtained for both MCTR2 (25–75%; p<0.05) and the new MCTR3 (35–50%;
p<0.05; n = 4 neutrophil preparations).
Using live-imaging microscopy, we next investigated the kinetics of E. coli phagocytosis by
human macrophages in order to gain insights into cellular mechanisms activated by MCTR. At
1nM, MCTR3 increased macrophage phagocytosis of fluorescently labeled E. coli as early as 30
min after addition; similar results were also obtained with MCTR1 and MCTR2 (Fig 4B). Of
note, at the 2h interval the new MCTR3 gave the highest increase in E. coli phagocytosis fol-
lowed by MCTR1 and MCTR2. These results demonstrate that MCTRs display potent anti-
inflammatory and pro-resolving actions where MCTR3 gave highest activity with human mac-
rophage phagocytic responses (MCTR3>MCTR1>MCTR2). While each of the MCTRs
proved to be a statistically significant and potent activator of macrophage phagocytosis (e.g.
efferocytosis) on its own, when added together none of the MCTR displayed synergy (Fig 4c)
in this critical resolution response.
MCTRs also regulated human neutrophil responses. Each of these molecules dose-depen-
dently regulated human neutrophil phagocytosis of E. coli with MCTR3 displaying higher
potency at promoting neutrophil phagocytosis at doses as low as 1pM-100pM, with ~60%
increase in phagocytosis when compared to both MCTR2 and MCTR3 (S1 Fig). MCTR1 and
MCTR3 each gave a bell-shaped curve that is characteristic of G protein-coupled receptor acti-
vation by SPM [17] that may reflect cellular shape changes at higher concentrations of the
mediators. MCTR2 gave two distinct peaks, suggesting this mediator may activate two distinct
receptors, a high affinity and low affinity receptor, on macrophages that mediate its actions in
regulating phagocytosis of E. coli.
Discussion
The present findings establish the complete stereochemistry of the first MCTR: MCTR1 as 13R-
glutathionyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-docosahexaenoic acid, for MCTR2
as 13R-cysteinylglycinyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-docosahexaenoic acid
and that for the new MCTR3 as 13R-cysteinyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-
docosahexaenoic acid, and their bioactions. These results also confirm the potent biological
actions of MCTR1 andMCTR2 originally uncovered [2] and now demonstrate that the new
member of the series MCTR3 carries potent, unanticipated bioactions governing the cardinal
signs of resolution, namely clearance of debris and infections by phagocytes, tissue regeneration,
and regulation of pro-inflammatory chemical mediators [3]. Together, these results assess the
overall rank order potencies of MCTRs at promoting the resolution of live bacterial infections as
MCTR3MCTR2>MCTR1 (see Fig 4).
Highly effective bioactive metabolic structure-function units are retained and copied
throughout evolution. This is exemplified by the diverse roles of the isoprenoid unit through-
out the biosphere with many biosynthetic pathways and wide ranging functions. Indeed this
structural unit is the building block of many biologically significant molecules including ste-
roids, retinoids and terpenoids [18]. By comparison, the enzymatically-produced allylic epox-
ides (Fig 1) central to maresin and SPM biosynthesis also appear to be highly conserved in
MCTR3 (100ng) or vehicle was administered via i.p. injection and peritoneal exudates collected 24h after E. coli inoculation; leukocyte counts were assessed
and resolution indices determined. (I) 24h exudate leukocyte counts (see Materials and Methods). (J) E. coli phagocytosis by exudate leukocytes was
determined as MFI in the CD11b+E. coli+ population. Results are mean±sem. n = 3 or 4 mice per group. *p<0.05, **p<0.01 vs. E. colimice. #p<0.05 vs. E.
coli + MCTR1.
doi:10.1371/journal.pone.0149319.g003
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Fig 4. MCTRs are anti-inflammatory and pro-resolving with human phagocytes. Humanmacrophages
(5 × 104 cells per well) were incubated with vehicle (DPBS+/+), MCTR 1, MCTR2 or MCTR3 (at the indicated
concentrations, 15 min, 37°C). Fluorescently labeled (A) E. coli (n = 8) were then added and phagocytosis
assessed after 60min using a fluorescent plate reader. Results are mean ± SEM. *p<0.05, **p<0.01,
#p<0.001, ##p<0.0001 vs. vehicle. (B) Human macrophages were plated onto chamber slides (6 x104 cells/
well) and incubated with MCTR1, MCTR2, MCTR3 (1 nM) or vehicle control (PBS+/+) for 15 min at 37°C,
followed by addition of BacLight Green-labeled E. coli. Fluorescent images were recorded every 6 min for 120
min. In each experiment, 4 fields (20X) per condition (per well) were recorded. Results are mean
fluorescence of 4 fields/well. n = 3 separate macrophage preparations. (C) E. coli phagocytosis by human
macrophages incubated with MCTRs individually or the indicated combinations of MCTRs added
simultaneously. Results are mean ± SEM for cells from n = 4 healthy human donors, *p<0.05 vs. vehicle
(macrophages with E. coli alone).
doi:10.1371/journal.pone.0149319.g004
MCTR Rank Order Potencies in Infection-Resolution
PLOS ONE | DOI:10.1371/journal.pone.0149319 February 16, 2016 10 / 12
chemical evolution as a central building block in the biosynthesis of diverse bioactive mole-
cules with wide ranging functions such the MCTR from 13S,14S-eMAR [2] and, for example,
CysLT from the epoxide intermediate leukotriene A4 [5, 19]. Of relevance to our present stud-
ies is the conjugation of allylic epoxides with sulfur-containing peptides that give rise to mole-
cules that carry potent infection-resolution properties (shown in Fig 1). The biological actions
of these molecules are also separate, whereby the cysteinyl leukotrienes carry potent broncho-
constrictive and inflammation-initiating actions [5, 20], whereas MCTR are potently pro-
resolving and function in tissue regeneration [2, 3]. MCTR3 enhanced both human PMN and
macrophage responses (Fig 4 and S1 Fig) yet did not appear to display synergy or alter PMN
survival in vitro in these conditions (S1 Table). Of interest, MCTR3 proved to be a potent bio-
active molecule with planaria, mouse, and human cells. Thus the present findings provide
new, highly conserved targets and pathways linking resolution of infections with tissue
regeneration.
Supporting Information
S1 Fig. MCTRs enhance human PMN phagocytosis and human macrophage efferocytosis
of apoptotic PMN. (A) Human neutrophil phagocytosis. Human neutrophils (1 × 105 cells per
well) were incubated with vehicle (DPBS+/+), MCTR 1, 2 or 3 (at the indicated concentrations,
15 min, 37°C). Fluorescently labeled E. coli (1:50) was then added and phagocytosis assessed
after 1 hour (n = 4). Results are mean ± SEM. p<0.05 vs. vehicle; determined using One-way
ANOVA. (B) Human macrophage efferocytosis. Human macrophages (5 × 104 cells per well)
were incubated with vehicle (DPBS+/+), MCTR 1, MCTR2 or MCTR3 (at the indicated concen-
trations, 15 min, 37°C). Fluorescently labeled apoptotic PMN (n = 5) were then added and
phagocytosis assessed after 60min using a fluorescent plate reader. Results are mean ± SEM.
p<0.05, p<0.01, #p<0.001, ##p<0.0001 vs. vehicle.
(PDF)
S1 Table. MCTRs and human PMN Survival in vitro.Human PMN were incubated for either
24 or 48 hours in DPBS+/+ (pH 7.2, 37°C, 5% CO2) in vehicle (DPBS
+/+ alone) or with the addi-
tion of 10nMMCTR1, MCTR2, or MCTR3 at time zero. Cell viability was assessed using flow
cytometry with surface staining for Annexin V and Propidium Iodide. Results are mean ± SEM
from n = 3 healthy volunteers. Annexin+, PI−represents early apoptotic PMN and Annexin+,
PI+ represents late apoptotic PMN populations. There were no statistically significant differ-
ences in apoptotic populations between vehicle (DPBS+/+ alone) and MCTR treated PMN by
one-tailed T-test.
(PDF)
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